Taken together, investigation of cathepsin B deficiency and cathepsin B overexpression in four unrelated genetic mouse models of de novo tumorigenesis showed consistently that cathepsin B is a tumor-promoting protease and, therefore, a potential therapeutic target. The gene discussed is CTSB; the disease is neoplasm.